Tian-Yuan Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tian-Yuan Xiong has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Mao Chen
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China
19 shared publications - Yuan Feng
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China
9 shared publications Yuan Feng
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, People's Republic of China
8 shared publications- Zhen-Gang Zhao
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China
7 shared publications - Yong Peng
Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China
6 shared publications Fei Chen
Sichuan University
5 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e047475
Outcomes of Transcatheter Aortic Valve Replacement in Mixed Aortic Valve Disease: A Comparison Between Bicuspid and Tricuspid Valves
Background: The impact of aortic valve morphology on outcomes after transcatheter aortic valve replacement in patients with mixed aortic valve disease, characterized by the coexistence of aortic stenosis and regurgitation, remains poorly defined. This study aimed to compare outcomes of transcatheter aortic valve replacement between bicuspid and tricuspid aortic valve morphologies in patients with mixed aortic valve disease. Methods: We retrospectively analyzed 282 patients with mixed aortic valve disease who underwent transcatheter aortic valve replacement between January 2019 and June 2024, including 82 with bicuspid aortic valve and 200 with tricuspid aortic valve. Propensity score matching at a 1:1 ratio yielded 82 well‐balanced pairs. The primary end point was all‐cause death, and secondary end points included technical success, paravalvular leak, clinical adverse events, hemodynamic performance, and left ventricular reverse remodeling. Results: Both groups achieved high technical success rates (97.6% versus 93.9%; P =0.443) with comparable procedural outcomes. Although mild or greater paravalvular leak occurred more frequently in the bicuspid aortic valve group, this difference did not translate into higher 1‐year all‐cause death (3.7% versus 3.7%; P >0.999) or adverse events. Hemodynamic performance and left ventricular remodeling improved significantly in both groups; however, patients with bicuspid aortic valve showed more pronounced increase in left ventricular ejection fraction (median, 6.5% [interquartile range, −2.0% to 15.5%] versus 0.5% [interquartile range, −5.0% to 12.0%]; P =0.023), whereas the degree of reverse remodeling was less evident (median, −7.0 [interquartile range, −17.0 to −3.0] versus −11.0 [interquartile range, −20.0 to −6.0] mm; P =0.045). Conclusions: In patients with mixed aortic valve disease undergoing transcatheter aortic valve replacement, bicuspid aortic valve morphology was associated with more mild or greater paravalvular leak but similar procedural safety, hemodynamic outcomes, and clinical prognosis compared with tricuspid aortic valve, with distinct left ventricular recovery patterns.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e047475
Open AccessOutcomes of Transcatheter Aortic Valve Replacement in Mixed Aortic Valve Disease: A Comparison Between Bicuspid and Tricuspid Valves
Background: The impact of aortic valve morphology on outcomes after transcatheter aortic valve replacement in patients with mixed aortic valve disease, characterized by the coexistence of aortic stenosis and regurgitation, remains poorly defined. This study aimed to compare outcomes of transcatheter aortic valve replacement between bicuspid and tricuspid aortic valve morphologies in patients with mixed aortic valve disease. Methods: We retrospectively analyzed 282 patients with mixed aortic valve disease who underwent transcatheter aortic valve replacement between January 2019 and June 2024, including 82 with bicuspid aortic valve and 200 with tricuspid aortic valve. Propensity score matching at a 1:1 ratio yielded 82 well‐balanced pairs. The primary end point was all‐cause death, and secondary end points included technical success, paravalvular leak, clinical adverse events, hemodynamic performance, and left ventricular reverse remodeling. Results: Both groups achieved high technical success rates (97.6% versus 93.9%; P =0.443) with comparable procedural outcomes. Although mild or greater paravalvular leak occurred more frequently in the bicuspid aortic valve group, this difference did not translate into higher 1‐year all‐cause death (3.7% versus 3.7%; P >0.999) or adverse events. Hemodynamic performance and left ventricular remodeling improved significantly in both groups; however, patients with bicuspid aortic valve showed more pronounced increase in left ventricular ejection fraction (median, 6.5% [interquartile range, −2.0% to 15.5%] versus 0.5% [interquartile range, −5.0% to 12.0%]; P =0.023), whereas the degree of reverse remodeling was less evident (median, −7.0 [interquartile range, −17.0 to −3.0] versus −11.0 [interquartile range, −20.0 to −6.0] mm; P =0.045). Conclusions: In patients with mixed aortic valve disease undergoing transcatheter aortic valve replacement, bicuspid aortic valve morphology was associated with more mild or greater paravalvular leak but similar procedural safety, hemodynamic outcomes, and clinical prognosis compared with tricuspid aortic valve, with distinct left ventricular recovery patterns.
- Open Access
Bailout valve-in-valve therapy during transcatheter aortic valve replacement in bicuspid and tricuspid aortic stenosis: an observational single-centre study in China
Background Bailout valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is a critical rescue strategy for procedural failure, yet evidence regarding its outcomes in bicuspid aortic valve (BAV) anatomy remains limited. Methods This retrospective, single-centre study analysed 1597 patients (48.3% BAV) undergoing TAVR. Patients were stratified by the requirement for bailout ViV, which was conducted for significant residual aortic regurgitation (AR) or valve embolisation. Predictors were identified via multivariate logistic regression. Early- and mid-term survival outcomes were compared using Inverse Probability of Treatment Weighting (IPTW) via entropy balancing. Results Bailout ViV was required in 6.20% of patients (BAV: 6.87%; tricuspid aortic valve (TAV): 5.57%). Larger annulus perimeter and significant residual AR after initial deployment were identified as consistent independent predictors of bailout ViV across all cohorts. Additionally, lower annulus calcification volume, non-repositionable self-expanding valves and the learning phase were predictors in the overall cohort. Significant mitral regurgitation and lower calcification volume in BAV and male sex in TAV cohorts were independent risk factors. IPTW-adjusted analysis revealed significantly higher 30-day all-cause (HR 3.09, p=0.019) and cardiovascular mortality (HR 3.49, p=0.021) in the bailout ViV group. However, no significant differences were observed in mid-term all-cause or cardiovascular mortality between groups. Conclusions Bailout ViV was associated with elevated early mortality but offered satisfactory mid-term survival. Key predictors include anatomical challenges (large annulus and insufficient calcification) and procedural factors (non-repositionable self-expanding valve, learning phase TAVR and significant residual AR after the first prosthesis).
Open AccessBailout valve-in-valve therapy during transcatheter aortic valve replacement in bicuspid and tricuspid aortic stenosis: an observational single-centre study in China
Background Bailout valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is a critical rescue strategy for procedural failure, yet evidence regarding its outcomes in bicuspid aortic valve (BAV) anatomy remains limited. Methods This retrospective, single-centre study analysed 1597 patients (48.3% BAV) undergoing TAVR. Patients were stratified by the requirement for bailout ViV, which was conducted for significant residual aortic regurgitation (AR) or valve embolisation. Predictors were identified via multivariate logistic regression. Early- and mid-term survival outcomes were compared using Inverse Probability of Treatment Weighting (IPTW) via entropy balancing. Results Bailout ViV was required in 6.20% of patients (BAV: 6.87%; tricuspid aortic valve (TAV): 5.57%). Larger annulus perimeter and significant residual AR after initial deployment were identified as consistent independent predictors of bailout ViV across all cohorts. Additionally, lower annulus calcification volume, non-repositionable self-expanding valves and the learning phase were predictors in the overall cohort. Significant mitral regurgitation and lower calcification volume in BAV and male sex in TAV cohorts were independent risk factors. IPTW-adjusted analysis revealed significantly higher 30-day all-cause (HR 3.09, p=0.019) and cardiovascular mortality (HR 3.49, p=0.021) in the bailout ViV group. However, no significant differences were observed in mid-term all-cause or cardiovascular mortality between groups. Conclusions Bailout ViV was associated with elevated early mortality but offered satisfactory mid-term survival. Key predictors include anatomical challenges (large annulus and insufficient calcification) and procedural factors (non-repositionable self-expanding valve, learning phase TAVR and significant residual AR after the first prosthesis).
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1) , 8817783
Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1) , 8817783
Open AccessTranscatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.
- Open Access
- 17 December 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9667-9679
Associations between blood cell-based inflammatory indices and their changes and mortality in patients undergoing transcatheter aortic valve replacement: a retrospective investigation with prospective multicenter cohort validation study
Background: Chronic inflammation is a driver of cardiovascular diseases, including valvular calcification. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and neutrophil percentage-to-albumin ratio (NPAR) are promising markers of systemic inflammation. However, research on the predictive value of dynamic changes in these indices for clinical outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) remains limited. Materials and methods: This study employed a retrospective single-center cohort (2012–2023, n = 1629) with validation in a prospective multicenter cohort (2023–2024, n = 443). The primary endpoint was all-cause mortality. All participants were stratified into tertiles based on pre- and post-TAVR values of NLR, PLR, and NPAR. Multivariate Cox proportional hazards regression models and restricted cubic spline (RCS) models were used to assess associations of pre-TAVR, post-TAVR, and dynamic changes in these three composite inflammatory markers with mortality. Receiver operating characteristic (ROC) curves and time-dependent Harrell’s C-index were applied to evaluate the time-varying predictive value of these markers for mortality. Results: Multivariable-adjusted Cox regression models showed that the highest tertile of inflammatory markers (both pre- and post-TAVR) was associated with a higher risk of all-cause mortality than the lowest tertile (pre-TAVR: NLR, aHR = 1.61, P = 0.032; PLR, aHR = 1.88, P = 0.003; NPAR, aHR = 1.69, P = 0.027). Multivariable-adjusted Cox regression and ROC analysis showed that post-TAVR inflammatory markers demonstrated a greater predictive value for mortality than pre-TAVR values. Time-dependent Harrell’s C-index analysis showed high and time-constant predictive values of the pre- and post-TAVR NLR, PLR, and NPAR for mortality. An increase in post-TAVR inflammatory markers from baseline was associated with a sharp rise in mortality risk. Replicate analyses in the multicenter prospective cohort validated the robustness of the findings from our single-center analysis. Conclusions: Post-TAVR NLR, PLR, and NPAR exhibit superior predictive value for mortality compared to pre-TAVR values, with NPAR being the most powerful predictor. Measurement of these three blood cell-based composite inflammatory markers enables precise risk stratification of TAVR patients. Further interventional studies targeting these markers, especially NPAR, are warranted.
- 17 December 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 9667-9679
Open AccessAssociations between blood cell-based inflammatory indices and their changes and mortality in patients undergoing transcatheter aortic valve replacement: a retrospective investigation with prospective multicenter cohort validation study
Background: Chronic inflammation is a driver of cardiovascular diseases, including valvular calcification. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and neutrophil percentage-to-albumin ratio (NPAR) are promising markers of systemic inflammation. However, research on the predictive value of dynamic changes in these indices for clinical outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) remains limited. Materials and methods: This study employed a retrospective single-center cohort (2012–2023, n = 1629) with validation in a prospective multicenter cohort (2023–2024, n = 443). The primary endpoint was all-cause mortality. All participants were stratified into tertiles based on pre- and post-TAVR values of NLR, PLR, and NPAR. Multivariate Cox proportional hazards regression models and restricted cubic spline (RCS) models were used to assess associations of pre-TAVR, post-TAVR, and dynamic changes in these three composite inflammatory markers with mortality. Receiver operating characteristic (ROC) curves and time-dependent Harrell’s C-index were applied to evaluate the time-varying predictive value of these markers for mortality. Results: Multivariable-adjusted Cox regression models showed that the highest tertile of inflammatory markers (both pre- and post-TAVR) was associated with a higher risk of all-cause mortality than the lowest tertile (pre-TAVR: NLR, aHR = 1.61, P = 0.032; PLR, aHR = 1.88, P = 0.003; NPAR, aHR = 1.69, P = 0.027). Multivariable-adjusted Cox regression and ROC analysis showed that post-TAVR inflammatory markers demonstrated a greater predictive value for mortality than pre-TAVR values. Time-dependent Harrell’s C-index analysis showed high and time-constant predictive values of the pre- and post-TAVR NLR, PLR, and NPAR for mortality. An increase in post-TAVR inflammatory markers from baseline was associated with a sharp rise in mortality risk. Replicate analyses in the multicenter prospective cohort validated the robustness of the findings from our single-center analysis. Conclusions: Post-TAVR NLR, PLR, and NPAR exhibit superior predictive value for mortality compared to pre-TAVR values, with NPAR being the most powerful predictor. Measurement of these three blood cell-based composite inflammatory markers enables precise risk stratification of TAVR patients. Further interventional studies targeting these markers, especially NPAR, are warranted.
- Open Access
- 29 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035772
Long‐Term Durability of Transcatheter Aortic Valve Prostheses in Patients With Bicuspid Versus Tricuspid Aortic Valve
Background: Currently, there is a lack of evidence for the long‐term bioprosthetic valve durability of patients with bicuspid aortic valve (BAV) following transcatheter aortic valve replacement (TAVR). Methods and Results: This study aimed to evaluate hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure during long‐term follow‐up after TAVR in patients with BAV versus patients with tricuspid aortic valve (TAV). Patients with BAV and TAV who underwent TAVR between 2012 and 2020, with echocardiography followed for at least 3 years, were included. Baseline characteristics, long‐term valve hemodynamic performance, structural valve deterioration, and bioprosthetic valve failure were compared between patients with BAV and TAV. A total of 170 patients with BAV and 145 patients with TAV were included. The mean duration of follow‐up for patients with BAV and TAV was 5.2±1.8 and 5.0±1.7 years. No significant differences were observed in the rates of structural valve deterioration and bioprosthetic valve failure between patients with BAV and TAV: structural valve deterioration, BAV 20 (11.8%) versus TAV 16 (11.0%) at last follow‐up ( P =0.861); bioprosthetic valve failure, BAV 3 (1.8%) versus TAV 7 (4.8%) at last follow‐up ( P =0.196). More than moderate intravalvular aortic regurgitation (1.8% versus 4.8%, P =0.196) and paravalvular leak (6.5% versus 3.4%, P =0.305) were rare in both patients with BAV and patients with TAV. Conclusions: This study indicated satisfactory long‐term valve durability of TAVR in patients with BAV. Comparable hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure could be achieved in patients with BAV and TAV during long‐term follow‐up after TAVR.
- 29 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035772
Open AccessLong‐Term Durability of Transcatheter Aortic Valve Prostheses in Patients With Bicuspid Versus Tricuspid Aortic Valve
Background: Currently, there is a lack of evidence for the long‐term bioprosthetic valve durability of patients with bicuspid aortic valve (BAV) following transcatheter aortic valve replacement (TAVR). Methods and Results: This study aimed to evaluate hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure during long‐term follow‐up after TAVR in patients with BAV versus patients with tricuspid aortic valve (TAV). Patients with BAV and TAV who underwent TAVR between 2012 and 2020, with echocardiography followed for at least 3 years, were included. Baseline characteristics, long‐term valve hemodynamic performance, structural valve deterioration, and bioprosthetic valve failure were compared between patients with BAV and TAV. A total of 170 patients with BAV and 145 patients with TAV were included. The mean duration of follow‐up for patients with BAV and TAV was 5.2±1.8 and 5.0±1.7 years. No significant differences were observed in the rates of structural valve deterioration and bioprosthetic valve failure between patients with BAV and TAV: structural valve deterioration, BAV 20 (11.8%) versus TAV 16 (11.0%) at last follow‐up ( P =0.861); bioprosthetic valve failure, BAV 3 (1.8%) versus TAV 7 (4.8%) at last follow‐up ( P =0.196). More than moderate intravalvular aortic regurgitation (1.8% versus 4.8%, P =0.196) and paravalvular leak (6.5% versus 3.4%, P =0.305) were rare in both patients with BAV and patients with TAV. Conclusions: This study indicated satisfactory long‐term valve durability of TAVR in patients with BAV. Comparable hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure could be achieved in patients with BAV and TAV during long‐term follow‐up after TAVR.
- Open Access
Long-term outcomes of TAVI patients undergoing different pacing modality: LBBAP versus RVP
Background: New-onset permanent pacemaker implantation (PPMI) is still a common complication after transcatheter aortic valve implantation (TAVI) with adverse clinical outcomes. This study aims to investigate whether left bundle branch area pacing (LBBAP) improves long-term clinical results compared to traditional right ventricular pacing (RVP) in patients requiring PPMI following TAVI. Methods: A total of 237 consecutive patients undergoing RVP (N=117) or LBBAP (N=120) following TAVI were retrospectively included. Long-term outcomes including all-cause death, heart failure rehospitalization (HFH) and left ventricular ejection fraction (LVEF) change compared to baseline were obtained until 5 years post-TAVI. Results: The mean age of the overall population was 74 years with a mean surgical risk score as 4.4%. The paced QRS duration was significantly shorter in LBBAP group compared to RVP group (151 ± 18 vs. 122 ±12 ms, P<0.001). There was no difference between two groups in all-cause death (13.7% vs. 13.3%, adjusted HR: 0.76; 95% CI: 0.37 to 1.58; P=0.466) or the composite endpoint of death and HFH (29.9% vs. 19.2%, adjusted HR: 1.22; 95% CI: 0.70 to 2.13; P=0.476), however, the risk of HFH was significantly reduced in LBBAP group compared to RVP at 5 years after TAVI (21.4% vs. 7.5%, adjusted HR: 2.26; 95% CI: 1.01 to 5.08; P=0.048). There was a more marked evolution of LVEF over time in LBBAP group (P=0.046 for LVEF changes over time between groups). Conclusions: LBBAP improved long-term clinical outcomes compared to RVP in patients undergoing PPMI after TAVI in terms of less HFH and better LVEF improvement.
Open AccessLong-term outcomes of TAVI patients undergoing different pacing modality: LBBAP versus RVP
Background: New-onset permanent pacemaker implantation (PPMI) is still a common complication after transcatheter aortic valve implantation (TAVI) with adverse clinical outcomes. This study aims to investigate whether left bundle branch area pacing (LBBAP) improves long-term clinical results compared to traditional right ventricular pacing (RVP) in patients requiring PPMI following TAVI. Methods: A total of 237 consecutive patients undergoing RVP (N=117) or LBBAP (N=120) following TAVI were retrospectively included. Long-term outcomes including all-cause death, heart failure rehospitalization (HFH) and left ventricular ejection fraction (LVEF) change compared to baseline were obtained until 5 years post-TAVI. Results: The mean age of the overall population was 74 years with a mean surgical risk score as 4.4%. The paced QRS duration was significantly shorter in LBBAP group compared to RVP group (151 ± 18 vs. 122 ±12 ms, P<0.001). There was no difference between two groups in all-cause death (13.7% vs. 13.3%, adjusted HR: 0.76; 95% CI: 0.37 to 1.58; P=0.466) or the composite endpoint of death and HFH (29.9% vs. 19.2%, adjusted HR: 1.22; 95% CI: 0.70 to 2.13; P=0.476), however, the risk of HFH was significantly reduced in LBBAP group compared to RVP at 5 years after TAVI (21.4% vs. 7.5%, adjusted HR: 2.26; 95% CI: 1.01 to 5.08; P=0.048). There was a more marked evolution of LVEF over time in LBBAP group (P=0.046 for LVEF changes over time between groups). Conclusions: LBBAP improved long-term clinical outcomes compared to RVP in patients undergoing PPMI after TAVI in terms of less HFH and better LVEF improvement.
- Open Access
Optimal treatment of asymptomatic patients with severe aortic stenosis: protocol of a prospective, multicentre, registry study
Introduction Decisions regarding the optimal timing of intervention for asymptomatic aortic stenosis (AS) are controversial. The study aims to identify potential risk factors for asymptomatic patients with severe AS that are associated with worse prognosis and to evaluate the benefits of early interventions for asymptomatic patients presenting with one or more additional risk factors. Methods and analysis This is a non-interventional, prospective, open-label, multicentre registry study across China. A total of 1000 patients will be enrolled and categorised as symptomatic or asymptomatic. The primary endpoint is the occurrence of all-cause mortality, stroke, acute myocardial infarction and heart failure-related hospitalisation at 1-year follow-up. In asymptomatic severe AS patients presenting with one or more risk factors, the occurrence rate of the primary endpoint between those who undergo transcatheter aortic valve replacement (TAVR) and those who do not will be compared. We will also compare the occurrence rate of the primary endpoint for asymptomatic severe AS patients with additional risk factors who undergo TAVR with those presenting with symptoms. This study is believed to provide additional evidence to help clinicians identify and refer severe AS patients who are asymptomatic but present with additional risk factors for early intervention of TAVR. Ethics and dissemination The study protocol has been approved by the local ethics committee of each participating site: West China Hospital, Sichuan University; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Second Hospital of Hebei Medical University; Tianjin Chest Hospital; and First Affiliated Hospital of Nanchang University. All participants will provide written informed consent. Study results will be published through academic conferences and peer-reviewed journals. Trial registration This study was registered at the Chinese Clinical Trial Registry (https:// www.chictr.org.cn), with the registration number ChiCTR2200064853.
Open AccessOptimal treatment of asymptomatic patients with severe aortic stenosis: protocol of a prospective, multicentre, registry study
Introduction Decisions regarding the optimal timing of intervention for asymptomatic aortic stenosis (AS) are controversial. The study aims to identify potential risk factors for asymptomatic patients with severe AS that are associated with worse prognosis and to evaluate the benefits of early interventions for asymptomatic patients presenting with one or more additional risk factors. Methods and analysis This is a non-interventional, prospective, open-label, multicentre registry study across China. A total of 1000 patients will be enrolled and categorised as symptomatic or asymptomatic. The primary endpoint is the occurrence of all-cause mortality, stroke, acute myocardial infarction and heart failure-related hospitalisation at 1-year follow-up. In asymptomatic severe AS patients presenting with one or more risk factors, the occurrence rate of the primary endpoint between those who undergo transcatheter aortic valve replacement (TAVR) and those who do not will be compared. We will also compare the occurrence rate of the primary endpoint for asymptomatic severe AS patients with additional risk factors who undergo TAVR with those presenting with symptoms. This study is believed to provide additional evidence to help clinicians identify and refer severe AS patients who are asymptomatic but present with additional risk factors for early intervention of TAVR. Ethics and dissemination The study protocol has been approved by the local ethics committee of each participating site: West China Hospital, Sichuan University; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Second Hospital of Hebei Medical University; Tianjin Chest Hospital; and First Affiliated Hospital of Nanchang University. All participants will provide written informed consent. Study results will be published through academic conferences and peer-reviewed journals. Trial registration This study was registered at the Chinese Clinical Trial Registry (https:// www.chictr.org.cn), with the registration number ChiCTR2200064853.
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12) , e013083
Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves
BACKGROUND: Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. The study aims to compare the outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy. METHODS: We enrolled consecutive patients undergoing transcatheter aortic valve replacement for severe AS between 2012 and 2022 in this single-center retrospective cohort study. The primary outcome was mortality, while secondary outcomes included in-hospital complications such as stroke and pacemaker implantation and transcatheter heart valve hemodynamic performance. RESULTS: The number of patients with AS with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy was 328, 302, and 642, respectively. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2% versus 1.7% versus 1.7%, P overall =0.522; 1 year: 10% versus 2.3% versus 6.2%, P overall =0.099) and all stroke (30 days: 1.0% versus 0.9% versus 0.0%, P overall =0.765; 1 year: 1.4% versus 1.6% versus 1.3%, P overall =NS) were nonsignificant, and the incidence of overall in-hospital complications was comparable among groups. Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44]; P =0.035). The proportion of patients with a mean residual gradient ≥20 mm Hg was the highest in those with type 0 bicuspid anatomy, although the need for permanent pacemaker implantation was the lowest in this group. CONCLUSIONS: Major clinical outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy are equivalent at short- and mid-term follow-up. These observations merit further exploration in prospective international registries and randomized controlled trials.
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12) , e013083
Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves
BACKGROUND: Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. The study aims to compare the outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy. METHODS: We enrolled consecutive patients undergoing transcatheter aortic valve replacement for severe AS between 2012 and 2022 in this single-center retrospective cohort study. The primary outcome was mortality, while secondary outcomes included in-hospital complications such as stroke and pacemaker implantation and transcatheter heart valve hemodynamic performance. RESULTS: The number of patients with AS with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy was 328, 302, and 642, respectively. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2% versus 1.7% versus 1.7%, P overall =0.522; 1 year: 10% versus 2.3% versus 6.2%, P overall =0.099) and all stroke (30 days: 1.0% versus 0.9% versus 0.0%, P overall =0.765; 1 year: 1.4% versus 1.6% versus 1.3%, P overall =NS) were nonsignificant, and the incidence of overall in-hospital complications was comparable among groups. Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44]; P =0.035). The proportion of patients with a mean residual gradient ≥20 mm Hg was the highest in those with type 0 bicuspid anatomy, although the need for permanent pacemaker implantation was the lowest in this group. CONCLUSIONS: Major clinical outcomes of transcatheter aortic valve replacement for AS in patients with type 0 bicuspid, type 1 bicuspid, and tricuspid aortic valve anatomy are equivalent at short- and mid-term follow-up. These observations merit further exploration in prospective international registries and randomized controlled trials.
- 20 June 2022
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 20 (1) , 52-67
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization
Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
- 20 June 2022
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 20 (1) , 52-67
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization
Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
- Open Access
- 31 December 2021
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 28 (6) , 983-985
Left atrial and left atrial appendage remodeling after transcatheter aortic valve replacement: Preliminary results
- 31 December 2021
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 28 (6) , 983-985
Open AccessLeft atrial and left atrial appendage remodeling after transcatheter aortic valve replacement: Preliminary results